Costa Joins MonoSol Rx BOD with over 40 Years of Leadership Experience
WARREN, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) — MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and address unmet needs, today announced the appointment of Santo “Sandy” Costa to the Company’s Board of Directors.
Mr. Costa brings a wealth of leadership expertise to the Board, with over 40 years’ experience in the pharmaceutical, health care, and life sciences industries, as well as leadership in the legal sector. Currently, Mr. Costa sits on the board of Cytokinetics Inc. and is chairman of Metabon Inc. He has served as a board member to numerous other public and private companies and charitable organizations. Mr. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, N.C.
Sandy Costa’s professional experience includes over 30 years in executive and senior operating management positions within the pharmaceutical, health care, and life sciences industries. In addition to his legal practice, Sandy’s experience includes President, Chief Operating Officer, and Vice Chairman of Quintiles Transnational Corp. where during his tenure he had responsibility for all operating divisions and worldwide business development. Other executive level experience includes Senior Vice President-Administration, General Counsel and Director, Glaxo Inc. Sandy is also a nationally recognized speaker on leadership, as well as legal and policy issues affecting the pharmaceutical industry.
Mr. Costa earned a B.S. in pharmacy and his J.D. from St. John’s University.
“I am quite pleased to have the opportunity to serve on the MonoSol Rx Board of Directors,” said Mr. Costa. “MonoSol Rx is a unique and innovative company that has repeatedly demonstrated the versatility of its lead product, PharmFilm®. In my time on the Board of Directors, it is my goal to see the Company expand even further with their partnership, research, and development initiatives.”
Keith Kendall, CEO of MonoSol Rx commented, “We are grateful to have Sandy as the newest member of our Board. His decades of successful executive leadership in the pharmaceutical industry make him an obvious choice for us. We are confident Mr. Costa will help MonoSol Rx continue to grow and influence the specialty pharmaceutical market.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx’s leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.